| 摘要 |
The invention provides and describes solid state 17alpha-ethynyl-androst-5-ene-3beta,7beta,17beta-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17alpha-ethynyl-androst-5-ene-3beta,7beta,17beta-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17alpha-ethynyl-androst-5-ene-3beta,7beta,17beta-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17alpha-ethynyl-androst-5-ene-3beta,7beta,17beta-triol and uses of such formulations in treating the described conditions.
|
